Anectine

(Succinylcholine)

ApprovedSmall molecule

HHikma Pharmaceuticals LLC

Anectine is one of 62 small molecule programs targeting Cesarean Section. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Cesarean SectionActive, not recruiting

Thoracoscopic SurgeryUnknown status

RocuroniumCompleted

Cesarean SectionApproved

Active, not recruiting

Thoracoscopic SurgeryPreclinical

Unknown status

RocuroniumPreclinical

Completed

Competition

Competitive Landscape

83 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Anectine

HHikma Pharmaceuticals LLC

Approved

1 2

Fentanyl-Morphine

SSeoul National University Hospital

Phase 3

2 3

Ondansetron, Dexamethasone

KKing Khaled Eye Specialist Hospital

Phase 3

1 4

Sebacoyl Dinalbuphine Ester

LLumosa Therapeutics Co., Ltd.

Phase 3

1 5

Morphine - .

RRambam Health Care Campus

Phase 3

1 6

Dynastat

Pfizer

Preclinical

1 7

Proamatine

Takeda

Preclinical

1 8

Duragesic

CCephalon

Preclinical

6 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

4 10

Catapres

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sugammadex3 trials

Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine

Completed·RRigshospitalet, Denmark·Phase 4·NCT00953550·61 enrolled

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00474253·115 enrolled

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00751179·161 enrolled

LCH2 trials

Fade Upon TOF Stimulation Induced by Succinylcholine

Completed·UUniversity of Toledo Health Science Campus·Phase 4·NCT02425449·19 enrolled

High-Resolution Solid-State Manometry of the Effect of Succinylcholine on Barrier Pressure

Completed·—·Phase 4·NCT05556408·14 enrolled

Rocuronium2 trials

Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study

Completed·UUniversity Hospital, Geneva·Phase 2·NCT01571908·280 enrolled

Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)

Completed·MMassachusetts General Hospital·N/A·NCT01441960·45 enrolled

Bronchoscopy2 trials

Comparing Intubating Conditions Using Succinylcholine or Rocuronium for Rigid Bronchoscopy

Suspended·—·N/A·NCT01996358·150 enrolled

Low Dose Mivacurium vs. Low Dose Succinylcholine for Rigid Bronchoscopy

Completed·—·N/A·NCT01966484·100 enrolled

Neuromuscular Blockade1 trial

Mask Ventilation Before and After Neuromuscular Blockade

Completed·UUniversity of Washington·Phase 4·NCT02237443·210 enrolled

12 more indications

Cesarean Section1 trial

Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine

Completed·—·Phase 4·NCT01941628·91 enrolled

Neostigmine1 trial

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 4·NCT02410590

Depression1 trial

Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression

Completed·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT02667353·110 enrolled

Statins1 trial

Effect of Succinylcholine on Patients Using Statins

Completed·TThe Cleveland Clinic·N/A·NCT00986583·70 enrolled

Thoracoscopic Surgery1 trial

Effects of Succinylcholine on Nonintubated Thoracoscopic Surgery

Unknown status·NNational Taiwan University Hospital·N/A·NCT03469323·30 enrolled

General Anesthesia1 trial

Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia

Terminated·HHopital Foch·Phase 4·NCT01579864·6 enrolled

Muscle Relaxant1 trial

Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy

Not yet recruiting·PPeng Liang·N/A·NCT06709066·240 enrolled

Sedation1 trial

General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke

Completed·RRennes University Hospital·Phase 3·NCT02822144·351 enrolled

Muscle Relaxation1 trial

Muscle Relaxation for Short Procedures

Completed·—·N/A·NCT01902641·105 enrolled

Complication1 trial

Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery

Completed·UUniversity of Chicago·Phase 4·NCT02635542·100 enrolled

Intensive Care1 trial

Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care

Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT00355368·420 enrolled

Neuromuscular Blocking Agents1 trial

Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals

Completed·JJakob Louis Thomsen··NCT02914119·30,430 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ANECTINE

NDA NDA008453

Jan 1, 1982

QUELICIN

NDA NDA008845

Jan 1, 1982

SUCOSTRIN

NDA NDA008847

Aug 20, 2021

SUCCINYLCHOLINE CHLORIDE

NDA NDA215143

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Succinylcholine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Succinylcholine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Succinylcholine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA215143). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Anectine. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Hikma Pharmaceuticals LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHikma Pharmaceuticals LLC

Patent Landscape[5]

Patent Cliff

Nov 2, 2041

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12295932Nov 2, 2041

Anectine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sugammadex3 trials

LCH2 trials

Rocuronium2 trials

Bronchoscopy2 trials

Neuromuscular Blockade1 trial

Cesarean Section1 trial

Neostigmine1 trial

Depression1 trial

Statins1 trial

Thoracoscopic Surgery1 trial

General Anesthesia1 trial

Muscle Relaxant1 trial

Sedation1 trial

Muscle Relaxation1 trial

Complication1 trial

Intensive Care1 trial

Neuromuscular Blocking Agents1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News